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Background: Lower plaque trauma may result in favorable late outcomes after coronary stenting. The Sparrow® Coronary Stent System 
(CardioMind, Inc. Sunnyvale, CA) is a 0.014” guidewire-based stent delivery platform combining the Sirolimus drug in a fully biodegradable SynBiosys 
polymer matrix on CardioMind’s nitinol stent platform. Stent release is achieved with a novel release mechanism which utilizes a principle of 
electrochemical dissolution. Both the Bare metal (BMS) and sirolimus eluting (DES) versions are under evaluation in the CARE II randomized clinical 
study.
Methods: CARE II is a prospective, multicenter and multinational (Asia, Australia/NZ, Brazil and Europe) randomized 3-arm clinical study. CARE II 
was designed to demonstrate the safety, efficacy and performance of the CardioMind Coronary DES Stent in the treatment of single de novo native 
coronary artery lesions < 20 mm long and 2.0 - 2.75 mm in reference diameter when compared to the Bare Metal Sparrow and Driver/MicroDriver 
(MDT) stents. The primary endpoint is 8 mo in-stent LLL with IVUS follow-up in a subset of the patients.
Results: The mean age of the CARE II patients (n=100) was 63 yr with 33% diabetic and 88% with history of hyperlipidemia. Procedural success 
with the BMS or DES versions was 94.9% (75/79) with lesion success at 100% (79/79). Lesion access with either the BM or DES Sparrow System as 
a front line guidewire was in >70% of patients. The mean vessel size and lesion length were 2.32 mm and 14.47mm. Post-procedure residual in-
stent stenosis was 10.3 %. Preliminary follow-up data will be presented comparing the DES to BMS and MDT arms.
Conclusions: CARE II clinical experience with the Sparrow’s electrically activated stent release system demonstrates the feasibility and safety of 
this platform in small coronary arteries with guidewire-like deliverability and good stent expansion. The tailored design of the fully biodegradable 
polymer platform on the ultra-thin nitinol struts of the Sparrow may provide improved outcomes in small vessels by enabling atraumatic stenting.
